Marker Therapeutics, Inc. (NASDAQ:MRKR) Major Shareholder Enterprise Associates 16 New Acquires 554,250 Shares

Marker Therapeutics, Inc. (NASDAQ:MRKR) major shareholder Enterprise Associates 16 New bought 554,250 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was bought at an average price of $3.20 per share, with a total value of $1,773,600.00. Following the transaction, the insider now directly owns 1,625,678 shares in the company, valued at $5,202,169.60. This represents a 51.73 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Marker Therapeutics Stock Performance

NASDAQ MRKR traded down $0.38 on Monday, reaching $3.42. 59,346 shares of the stock traded hands, compared to its average volume of 31,081. Marker Therapeutics, Inc. has a 12 month low of $2.44 and a 12 month high of $6.16. The firm’s fifty day simple moving average is $3.71 and its 200 day simple moving average is $3.84.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Marker Therapeutics stock. Wedbush Securities Inc. raised its holdings in Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 69,500 shares of the company’s stock after acquiring an additional 24,000 shares during the quarter. Wedbush Securities Inc. owned 0.78% of Marker Therapeutics worth $377,000 as of its most recent filing with the Securities and Exchange Commission. 22.39% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH upped their price target on shares of Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, October 21st.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.